A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2018 Status changed from not yet recruiting to recruiting.
- 08 Dec 2017 Planned initiation date changed from 1 Oct 2017 to 1 Jan 2018.